Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway

Fig. 2

In vitro activity of 2b. a–d Viability of LLC, 95D, A549-TAX and A549 cancer cells treated with different concentrations of 2b and 100 μM NAMI-A. The concentrations of 2b were 6.25, 12.5, 25, 50, and 100 μM. e Morphological changes in cells in the control and administration groups incubated with 5% CO2 at 37 °C for 48 h. f Intracellular uptake of Ru in the 20 μM group. g, h Western blotting image and relative gray value analysis of proteins in A549 cells treated with 2b. i Quantitative real-time PCR results in A549 cells treated with 2b. j Gene function classification (GO) of 2b

Back to article page